Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical tr… Read more
Gossamer Bio Inc (GOSS) - Total Assets
Latest total assets as of September 2025: $208.82 Million USD
Based on the latest financial reports, Gossamer Bio Inc (GOSS) holds total assets worth $208.82 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Gossamer Bio Inc - Total Assets Trend (2016–2024)
This chart illustrates how Gossamer Bio Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Gossamer Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Gossamer Bio Inc's total assets of $208.82 Million consist of 98.3% current assets and 1.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.6% |
| Accounts Receivable | $5.34 Million | 1.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Gossamer Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gossamer Bio Inc's current assets represent 98.3% of total assets in 2024, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 14.6% of total assets in 2024, down from 100.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.
Gossamer Bio Inc Competitors by Total Assets
Key competitors of Gossamer Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Gossamer Bio Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Gossamer Bio Inc generates 0.36x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Gossamer Bio Inc is currently not profitable relative to its asset base.
Gossamer Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.28 | 6.74 | 13.51 |
| Quick Ratio | 3.28 | 6.74 | 13.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $141.87 Million | $ 293.18 Million | $ 483.67 Million |
Gossamer Bio Inc - Advanced Valuation Insights
This section examines the relationship between Gossamer Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.66 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | 1.1% |
| Total Assets | $315.29 Million |
| Market Capitalization | $90.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Gossamer Bio Inc's assets below their book value (0.29 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Gossamer Bio Inc's assets grew by 1.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Gossamer Bio Inc (2016–2024)
The table below shows the annual total assets of Gossamer Bio Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $315.29 Million | +1.08% |
| 2023-12-31 | $311.92 Million | +14.49% |
| 2022-12-31 | $272.45 Million | -20.72% |
| 2021-12-31 | $343.66 Million | -36.29% |
| 2020-12-31 | $539.43 Million | +26.45% |
| 2019-12-31 | $426.60 Million | +78.18% |
| 2018-12-31 | $239.42 Million | +53702.02% |
| 2017-12-31 | $445.00K | +641.67% |
| 2016-12-31 | $60.00K | -- |